Thursday, 04. April 2018
Breath Therapeutics’ lead drug candidate, L-CsA-i, is a proprietary liposomal formulation of cyclosporine A for inhalation administered via a drug-specific investigational eFlow® Technology nebuliser.
Tuesday, 02. October 2018
ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
Thursday, 07. December 2017
LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.